Prolocor
Philadelphia, US · Founded 2020 · Delaware corporation · 2 known investors
Find your way into Prolocor
Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.
Founders & leadership
Prolocor was founded in 2020 by Peter M. DiBattiste and David J. Schneider.
Investors · 2
Also in the syndicate · 1
Labcorp
Funding
SEC filings, press & company announcements$1.6M disclosed across 1 of 3 rounds · 2021–2024
- Undisclosed amountBridgeMar 2024Source ↗
- Undisclosed amountseed roundAug 2022
Green Park & Golf Ventures (lead), Labcorp
Source ↗
▶$1.6MraisedJan 2022 · 11 investors · Biotechnology
▶$1.6MraisedJan 2022 · 11 investors · Biotechnology
Officers, directors & promoters on the filing
- Peter M. DiBattisteExecutive Officer, Director
- David SchneiderExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.6M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 04.3
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCapricor3 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
AliveCor3 shared keywordsAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.
Companies competing with Prolocor for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Prolocor do?
- Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.
- Who founded Prolocor?
- Prolocor was founded by Peter M. DiBattiste, David J. Schneider in 2020.
- Who are Prolocor's investors?
- Prolocor's investors include Green Park & Golf Ventures.
- How much funding has Prolocor raised?
- Prolocor has disclosed $1.6M raised across 1 of its 3 known rounds.
- Where is Prolocor headquartered?
- Prolocor is headquartered in Philadelphia, US.